Literature DB >> 15880068

Direct visualization of cortical peritubular capillary of transplanted human kidney with reperfusion injury using a magnifying endoscopy.

Ryohei Hattori1, Yoshinari Ono, Masashi Kato, Tomonori Komatsu, Yoshihisa Matsukawa, Tokunori Yamamoto.   

Abstract

BACKGROUND: We developed a direct imaging system of renal microcirculation by a magnifying-endoscopy that enables visualization of the movement of erythrocyte in glomerular and cortical peritubular capillary (CPC). We investigated the microcirculation of CPC in the early phase of both living- and cadaveric-donor transplant kidneys.
METHODS: Erythrocyte velocity in CPC were monitored and measured in 20 renal transplants at 20, 60, 90, and 120 minutes after reperfusion. The kidney grafts came from 11 living donors and 9 non-heart-beating cadaveric donors.
RESULTS: In living-donor transplants, erythrocyte velocity in CPC at 20 minutes after revascularization declined to one third of baseline value just before nephrectomy and recovered to the prenephrectomy value 120 minutes after reperfusion. In contrast, it continued to be disturbed for 90 minutes in cadaveric-donor transplants. Erythrocyte velocity in CPC more significantly deteriorated in cadaveric transplants than in those of living transplants at 20 through 60 minutes after the revascularization. In living-donor transplants, erythrocyte velocity did not correlate with donor age, both warm (WIT) and cold ischemic time (CIT), time to the initial urination, and best creatine clearance. In the cadaveric transplants, ischemic time, both WIT and CIT, did not correlate with the erythrocyte velocity. However, donor age, duration of acute tubular necrosis, and best creatine clearance after transplantation significantly correlated with the erythrocyte velocity.
CONCLUSION: The measurement of erythrocyte velocity in CPC is a reliable method for predicting the recovery of renal function and reserved renal function of kidney allografts undergoing prolonged ischemia.

Entities:  

Mesh:

Year:  2005        PMID: 15880068     DOI: 10.1097/01.tp.0000160760.70984.25

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  6 in total

1.  Visual enhancement of laparoscopic partial nephrectomy with 3-charge coupled device camera: assessing intraoperative tissue perfusion and vascular anatomy by visible hemoglobin spectral response.

Authors:  Nicole J Crane; Suzanne M Gillern; Kambiz Tajkarimi; Ira W Levin; Peter A Pinto; Eric A Elster
Journal:  J Urol       Date:  2010-08-17       Impact factor: 7.450

2.  Contrast enhancement for in vivo visible reflectance imaging of tissue oxygenation.

Authors:  Nicole J Crane; Zachary D Schultz; Ira W Levin
Journal:  Appl Spectrosc       Date:  2007-08       Impact factor: 2.388

Review 3.  Renal oxygenation and haemodynamics in acute kidney injury and chronic kidney disease.

Authors:  Prabhleen Singh; Sven-Erik Ricksten; Gudrun Bragadottir; Bengt Redfors; Lina Nordquist
Journal:  Clin Exp Pharmacol Physiol       Date:  2013-02       Impact factor: 2.557

4.  Quantitative Micro-Computed Tomography Imaging of Vascular Dysfunction in Progressive Kidney Diseases.

Authors:  Josef Ehling; Janka Bábíčková; Felix Gremse; Barbara M Klinkhammer; Sarah Baetke; Ruth Knuechel; Fabian Kiessling; Jürgen Floege; Twan Lammers; Peter Boor
Journal:  J Am Soc Nephrol       Date:  2015-07-20       Impact factor: 10.121

5.  TEMPOL has limited protective effects on renal oxygenation and hemodynamics but reduces kidney damage and inflammation in a rat model of renal ischemia/reperfusion by aortic clamping.

Authors:  Bulent Ergin; Rick Bezemer; Asli Kandil; Cihan Demirci-Tansel; Can Ince
Journal:  J Clin Transl Res       Date:  2015-09-30

6.  Non-invasive monitoring of tissue oxygenation during laparoscopic donor nephrectomy.

Authors:  Nicole J Crane; Peter A Pinto; Douglas Hale; Frederick A Gage; Doug Tadaki; Allan D Kirk; Ira W Levin; Eric A Elster
Journal:  BMC Surg       Date:  2008-04-17       Impact factor: 2.102

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.